Reliability meets palatability in CLAVAMOX® CHEWABLE
(amoxicillin and clavulanate potassium tablets).

**Feature/Function:**
In a FDA-approved study CLAVAMOX CHEWABLE, featuring the same pork-liver-flavored base as RIMADYL® (carprofen) Chewable had an overall voluntary acceptance rate of 83%.**2**

**Benefit:**
CLAVAMOX CHEWABLE is a highly palatable medication that pets will love!

**Feature/Function:**
Easy-to-Administer

**Benefit:**
CLAVAMOX CHEWABLE provides relief to pet owners and your staff from the stress and anxiety of struggling to medicate pets. Additionally, it can help overcome compliance issues.

**Feature/Function:**
Same indications, strengths, dosing, and efficacy of original CLAVAMOX Tablets.

**Benefit:**
Helps improve the health of your patients and practice with the preferred veterinary antibiotic, trusted for more than 30 years.**3**

**Feature/Function:**
CLAVAMOX CHEWABLE is available in 100-count boxes instead of 210–count boxes.

**Benefit:**
Smaller box size reduces inventory costs and losses associated with unused, expired tablets.

IMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CLAVAMOX. Do not use in animals with a history of allergic reactions to penicillins or cephalosporins.

See Brief Summary of full Prescribing Information on page XX.

---

*Not actual size.

**One hundred twelve (112) dogs with 1567 total tablet administrations successfully completed the study and were included in the data summary. Of the 1567 doses administered, CLAVAMOX CHEWABLE tablets were fully consumed within five minutes 82.51% of the time. Tablets were fully consumed within two minutes 81.17% of the time. The percent acceptance was consistent over 14 doses (seven days). For the first dose given, 93/112 dogs (83.04%) consumed the entire dose within two minutes. For the last (14th) dose, 89/111 dogs (80.18%) consumed the entire dose within two minutes, indicating that tablet acceptability continued over time without development of aversion to the tablet(s).

• Approved for cats and dogs.
• Same indications, strengths, dosing and efficacy of original film-coated CLAVAMOX Tablets.
• Preferred veterinary antibiotic.³
• 60+ years of innovation and dedication by Zoetis to making animals’ lives better, fueled by your support of medications like CLAVAMOX.

• Smaller Pack Size: 100 chewable tablets per box instead of 210-count boxes like the original.
• Help patient compliance with highly palatable, easy-to-administer CLAVAMOX CHEWABLE.
• Pet owners and patients will love CLAVAMOX CHEWABLE, and they’ll love you for prescribing it.

In a well-controlled U.S. field study that included 1,567 doses administered to 112 dogs, CLAVAMOX CHEWABLE received 83% overall voluntary acceptance from an empty bowl or owner’s hand.**²

**Sound Byte**

State the Solution

CLAVAMOX CHEWABLE is an easy-to-administer chewable with high palatability. In fact most dogs will voluntarily take it out of your hand or from their food bowl.

Start an Effective Team to Pet Owner Conversation

If engaging in an initial diagnosis, start with:

Ms. Jones, we’re going to need to prescribe a broad-spectrum antibiotic for Spot. I understand that in the past you’ve had trouble getting Spot to take his medicine in tablet form.

Make Your Recommendation

I am prescribing CLAVAMOX CHEWABLE for Spot so that you don’t have to struggle to give him his antibiotic, making it easier for you to give him the treatment he needs.
Streptococcus spp., Staphylococcus aureus-lactamase-producing skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermatitis.

In cats:
Periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.

In dogs:
Skin and soft tissue infections such as wounds, cellulitis, superficial/multiloculation pyoderma, and periodontal infections should be treated for 5–7 days of treatment, after all symptoms have subsided. If no response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.

**INDICATIONS:** CLAVAMOX CHEWABLE Tablets are indicated in the treatment of:

**Dogs:** Skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and E. coli. Periarticular infections due to susceptible strains of both aerobic and anaerobic bacteria. CLAVAMOX CHEWABLE has been shown to be clinically effective for treating cases of canine periodontal disease.

**Cats:** Skin and soft tissue infections such as wounds, abscesses, and cellulitis/dermattis due to susceptible strains of the following organisms: β-lactamase-producing Staphylococcus aureus, non-β-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., Corynebacterium pyogenes, Corynebacterium species, Esreyphilothrix rhusiopathiae, Bordetella bronchiseptica, Escerichia coli*, Proteus mirabilis, Proteus species, Enterobacter species, Klebsiella pneumoniae, Salmonella dublin, Salmonella typhimurium, Pasteurella multocida, Pasteurella hemolytica, Pasteurella species**.

The susceptibility of these organisms has also been demonstrated in vivo studies. Studies have demonstrated that both aerobic and anaerobic flora are isolated from gingival cultures of dogs with clinical evidence of periodontal disease. Both gram-positive and gram-negative aerobic and anaerobic subgingival isolates indicate sensitivity to amoxicillin/clavulanate acid during antimicrobial susceptibility testing.


**PALATABILITY:** The palatability of CLAVAMOX CHEWABLE Tablets was evaluated in a multi-location field trial. One hundred twelve (112) client-owned dogs were dosed with CLAVAMOX CHEWABLE Tablets at 6.25 mg/lb (12.5 mg/kg) twice daily for 7 days and evaluated for palatability of the product. Dogs freely consumed 83% of their doses within 5 minutes of offering from an empty bowl or owner’s hand. Of the 17% of doses not consumed after 5 minutes, 16% were administered with a treat or food/force injection and 1% of doses were refused.

**STORAGE INFORMATION:** Store in a dry, cool place at temperatures not above 25°C (77°F). Do not remove from foil strip until ready to use.

**HOW SUPPLIED:** CLAVAMOX CHEWABLE Tablets in the following strengths are supplied in strip packs. Each carton holds 10 strips with 10 tablets per strip (100 tablets per carton).

- Each 62.5-mg tablet contains amoxicillin trihydrate equivalent to 50 mg of amoxicillin activity and 12.5 mg of clavulanic acid as the potassium salt. For use in dogs and cats.
- Each 125-mg tablet contains amoxicillin trihydrate equivalent to 100 mg of amoxicillin activity and 25 mg of clavulanic acid as the potassium salt. For use in dogs only.
- Each 250-mg tablet contains amoxicillin trihydrate equivalent to 200 mg of amoxicillin activity and 50 mg of clavulanic acid as the potassium salt. For use in dogs only.
- Each 375-mg tablet contains amoxicillin trihydrate equivalent to 300 mg of amoxicillin activity and 75 mg of clavulanic acid as the potassium salt. For use in dogs only.

Dispense according to recommendations outlined in Dosage and Administration section.

**NADA #55-099. Approved by FDA**

CLAVAMOX is a trademark owned by and used under license from GlaxoSmithKline. Augmentin is a trademark owned by GlaxoSmithKline. Manufactured by: Haupt Pharma, Latina, Italy. Distributed by: Zoetis Inc. Kalamazoo, MI 49007 Revised: March 2017 MADE IN ITALY

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth.

**ACTIONS:** The 2 components are rapidly absorbed resulting in amoxicillin and clavulanic acid concentrations in serum, urine, and tissues similar to those produced when each is administered alone.

Amoxicillin and clavulanic acid diffuse readily into most body tissues and fluids with the exception of brain and spinal fluid, which amoxicillin penetrates adequately when meninges are inflamed. Most of the amoxicillin is excreted unchanged in the urine. Clavulanic acid’s penetration into spinal fluid is unknown at this time. Approximately 15% of the administered dose of clavulanic acid is excreted in the urine within the first 24 hours.

CLAVAMOX CHEWABLE combines the distinctive properties of a broad-spectrum antibiotic and β-lactamase inhibitor to effectively extend the antibacterial spectrum of amoxicillin to include β-lactamase-producing as well as non-β-lactamase-producing aerobic and anaerobic organisms.

**MICROBIOLOGY:** Amoxicillin is bactericidal in action and acts through the inhibition of biosynthesis of cell wall mucoproteide of susceptible organisms. The action of clavulanic acid extends the antimicrobial spectrum of amoxicillin to include organisms resistant to amoxicillin and other β-lactam antibiotics. Amoxicillin/clavulanate has been shown to have a wide range of activity which includes β-lactamase-producing strains of both gram-positive and gram-negative facultative anaerobes, obligate anaerobes, and obligate anaerobes. Many strains of the following organisms, including β-lactamase-producing strains, isolated from veterinary sources, were found to be susceptible to amoxicillin/clavulanate in vitro but the clinical significance of this activity has not been demonstrated for some of these organisms in animals.


The susceptibility of these organisms has also been demonstrated in vivo studies. Studies have demonstrated that both aerobic and anaerobic flora are isolated from gingival cultures of dogs with clinical evidence of periodontal disease. Both gram-positive and gram-negative aerobic and anaerobic subgingival isolates indicate sensitivity to amoxicillin/clavulanic acid during antimicrobial susceptibility testing.